Literature DB >> 23794430

[Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists: treatment of diabetic maculopathy (April 2013)].

F Ziemssen, H Helbig, K D Lemmen, G Spital, B Bertram, J Hillenkamp, K U Bartz-Schmidt, N Bornfeld, M Bresgen, N Eter, W Friedrichs, H Heimann, H Hoerauf, F G Holz, A Kampik, B Kirchhof, D Pauleikhoff, J Roider.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23794430     DOI： 10.1055/s-0032-1328663

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN： 0023-2165            Impact factor:   0.700


× No keyword cloud information.
  5 in total

1.  [National guidelines for treatment of diabetic retinopathy : Second edition of the national guidelines for treatment of diabetic retinopathy].

Authors:  F Ziemssen; K Lemmen; B Bertram; H P Hammes; H Agostini
Journal:  Ophthalmologe       Date:  2016-07       Impact factor: 1.059

2.  Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data.

Authors:  Focke Ziemssen; Patricio G Schlottman; Jennifer I Lim; Hansjürgen Agostini; Gabriele E Lang; Francesco Bandello
Journal:  Int J Retina Vitreous       Date:  2016-07-11

3.  Ellipsoid Zone Integrity and Visual Acuity Changes during Diabetic Macular Edema Therapy: A Longitudinal Study.

Authors:  Lucy J Kessler; Gerd U Auffarth; Dmitrii Bagautdinov; Ramin Khoramnia
Journal:  J Diabetes Res       Date:  2021-10-07       Impact factor: 4.011

4.  Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients.

Authors:  Christoph Ehlken; Mandy Helms; Daniel Böhringer; Hansjürgen T Agostini; Andreas Stahl
Journal:  Clin Ophthalmol       Date:  2017-12-20

5.  Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.

Authors:  Thomas Wecker; Christoph Ehlken; Anima Bühler; Clemens Lange; Hansjürgen Agostini; Daniel Böhringer; Andreas Stahl
Journal:  Br J Ophthalmol       Date:  2016-05-23       Impact factor: 4.638
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.